The Indo-Asian News Service, the leading of its kind among the media in the country, said that the drug was developed after 15 years of research and has been successfully administered to more than a thousand patients on the island, reported Prensa Latina.
The product is registered in Peru and is in that process in Colombia, Brazil, Paraguay, Ecuador, Argentina and other Latin American countries, while they are planning to do the same in Australia, Thailand and Malaysia.
Citing the Cuban pharmaceutical industry, IANS said that clinical trials in Britain will be held in the coming weeks.
Cuban experts pointed out that the vaccine cannot prevent cancer, but can control it in its advanced stages by generating antibodies that act against proteins that trigger the cell proliferation processes.
The product is safe, has no severe side effects and increases the life expectancy of the patient, said project director, Gisela Gonzalez.
According to the World Health Organization, cancer is the leading cause of death worldwide, and lung cancer, one of the most common types.